1. MabVax Therapeutics
1.1 Business Overview
1.2 MabVax Therapeutics Cancer Pipeline Overview

2. MabVax Therapeutics Cancer Drugs in Research Phase
2.1 Chimeric Antigen Receptor T Cell Therapeutics - MabVax/MSKCC

3. MabVax Therapeutics Cancer Drugs in Preclinical Phase
3.1 HuMab 5B1 Radioimmunotherapy - MabVax
3.2 Anticancer Monoclonal Antibodies - MabVax/MSKCC
3.3 Ezatiostat Analogues - MabVax
3.4 Alkylating Agents - MabVax

4. MabVax Therapeutics Cancer Drugs in Phase-I
4.1 MVT 2163
4.2 MVT 5873

5. MabVax Therapeutics Cancer Drugs in Phase-I/II
5.1 Neuroblastoma Vaccine - MabVax/MSKCC

6. MabVax Therapeutics Cancer Drugs in Phase-II
6.1 Ovarian Cancer Vaccine - MabVax/MSKCC

7. No Development Reported in Cancer Drugs in Clinical Pipeline
7.1 Breast Cancer Vaccine - MabVax/MSKCC
7.2 Small Cell Lung Cancer Vaccine - MabVax/MSKCC
7.3 Melanoma Vaccine - MabVax/Memorial Sloan-Kettering Cancer Center


List of Figures

Figure 1-1: MabVax Therapeutics Cancer Pipeline by Phase (%)
Figure 1-2: MabVax Therapeutics Cancer Pipeline by Phase (Number)